Temporal changes in the control of blood pressure in an older Australian population

Journal of Human Hypertension

Volumn 19, Issue 9, 2005, Pages 691-696

  Chua, B ^a   Rochtchina, E ^a   Mitchell, Paul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adequacy; Blood pressure; Blue Mountains Eye Study; Control; Treatment; Trend

Indexed keywords

TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; AUSTRALIA; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; FEMALE; HEALTH PROGRAM; HEALTH PROMOTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL EXAMINATION; PHYSICAL ACTIVITY; POPULATION RESEARCH; PREVALENCE; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AGING; AUSTRALIA; BLOOD PRESSURE; BODY MASS INDEX; EXERCISE; FEMALE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; TIME FACTORS;

EID: 31044439447     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001881     Document Type: Article

References (48)

1. Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
2. National Heart Foundation of Australia. Hypertension Management Guide for Doctors 2004, pp. 1-24. www.heartfoundation.com.au/downloads/ hypertension_management_guide_2004.pdf.
3. Klag MJ et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293-1298.
4. Kannel WB. Cardioprotection and antihypertensive therapy: The key importance of addressing the associated coronary risk factors (the Framingham experience). Am J Gardiol 1996; 77: 6B-11B.
5. Lloyd-Jones DM, Evans JC, Larson MG, Levy D. Treatment and control of hypertension in the community: A prospective analysis. Hypertension 2002; 40: 640-646.
6. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995; 18: 181-196.
7. Pringle E et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003; 21: 2251-2257.
8. Himmelmann A et al. Isolated systolic hypertension: An important cardiovascular risk factor. Blood Press 1998; 7: 197-207.
9. Mancia G, Giannattasio C, Grassi G. Current anti-hypertensive treatment: can we do better? Am J Hypertens 1999; 12: 131S-138S.
10. Kannel WB, Vasan RS, Levy D. Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? Hypertension 2003; 42: 453-456.
11. Walker WG et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992; 268: 3085-3091.
12. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 summary. Adv Data 2002, 1-32.
13. Britt H; et al. General practice activity in Australia 2000-01. 2001, AIHW Cat. No GEP 8.
14. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
15. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: Results from the health survey for England 1998. Hypertension 2001; 38: 827-832.
16. Wolf-Maier K et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.
17. Briganti EM et al. Untreated hypertension among Australian adults: The 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 2003; 179: 135-139.
18. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001; 161: 1621-1628.
19. Lloyd A, Schmieder C, Marchant N. Financial and health costs of uncontrolled blood pressure in the United Kingdom. Pharmacoeconomics 2003; 21 (Suppl 1): 33-41.
20. Chia EM et al. Impact of bilateral visual impairment on health-related quality of life: The Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2004; 45: 71-76.
21. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450-1460.
22. World Health Organization, International Society of Hypertension Writing Group. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
23. Chaudhry SI, Krumholz HM, Foody JM. Systolic hypertension in older persons. JAMA 2004; 292: 1074-1080.
24. Australian Bureau of Statistics. Census: Basic Community Profile. Australian Bureau of Statistics: Canberra, (2001).
25. Breslow NE, Day NE. In: Statistical Methods in Cancer Research, Vol II. International Agency for Research on Cancer: Lyon, 1987, pp 48-79.
26. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1988; 41: 155-178.
27. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276.
28. Anderson TW. Re-examination of some of the Framingham blood-pressure data. Lancet 1978; 2: 1139-1141.
29. Rodgers A et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 1996; 313: 147.
30. Burt VL et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26: 60-69.
31. Fields LE et al. The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension 2004; 44: 398-404.
32. Truelsen T et al. Trends in stroke and coronary heart disease in the WHO MONICA Project. Stroke 2003; 34: 1346-1352.
33. Marques-Vidal P, Ruidavets JB, Cambou JP, Ferrieres J. Trends in hypertension prevalence and management in Southwestern France, 1985-1996. J Clin Epidemiol 2000; 53: 1230-1235.
34. Arnett DK et al. Fifteen-year trends in cardiovascular risk factors (1980-1982 through 1995-1997): The Minnesota Heart Survey. Am J Epidemiol 2002; 156: 929-935.
35. Evans A et al. Trends in coronary risk factors in the WHO MONICA project. Int J Epidemiol 2001; 30(Suppl 1): S35-S40.
36. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: Results from the health survey for England 1994. J Hypertens 1998; 16: 747-752.
37. Psaty BM et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: The Cardiovascular Health Study. Arch Intern Med 2002; 162: 2325-2332.
38. Wilson PW et al. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Intern Med 2002; 162: 1867-1872.
39. Folsom AR et al. Associations of general and abdominal obesity with multiple health outcomes in older women: The Iowa Women's Health Study. Arch Intern Med 2000; 160: 2117-2128.
40. Brown CD et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8: 605-619.
41. Steinberg HO et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
42. Vigili DK, Kiwanuka E, Tiengo A, Avogaro A. Visceral obesity is characterized by impaired nitric oxide-independent vasodilation. Eur Heart J 2003; 24: 1210-1215.
43. Pescatello LS et al. American College of Sports Medicine position stand. Exercise and hypertension. Med Sci Sports Exerc 2004; 36: 533-553.
44. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
45. Davis BR et al. Rationale and design for the Anti-hypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9: 342-360.
46. Black HR et al. Baseline characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension 2001; 37: 12-18.
47. Wiklund I, Halling K, Ryden-Bergsten T, Fletcher A. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997; 6: 357-364.
48. Grimm Jr RH et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997; 157: 638-648.